Research & Outreach Committee

Allergy, asthma and clinical immunology research has many challenges, including complex European regulations, funding opportunities, data gathering and overall quality control. To address these unmet needs, the newly formed EAACI Research and Outreach Committee (EAACI ROC) will develop an innovative research and knowledge exchange network, which will ensure the position of the EAACI as the global leader in promoting and supporting Research and Development.

About

Allergy, asthma and clinical immunology research has many challenges, including complex European regulations, funding opportunities, data gathering and overall quality control. To address these unmet needs, the newly formed EAACI Research and Outreach Committee (EAACI ROC) will develop an innovative research and knowledge exchange network, which will ensure the position of the EAACI as the global leader in promoting and supporting Research and Development.

Aims

  • Facilitate allergy, asthma and clinical immunology research through the coordination and support of the research community.
  • Support high quality and reproducible data by leveraging resources into a joint information exchange network while boosting top-notch experimental research through multicenter collaborations and strengthen the validity of the experimental medicine results.
  • Deliver new forms of translation of key research findings, to better meet the needs of clinicians and more quickly develop precision approaches to improve and cure allergic disease and asthma.
  • Facilitate basic and clinical research career development by expanding the funding opportunities for EAACI fellowships, develop educational and training programmes on cutting edge research methodologies,
  • Facilitate access of EAACI members to research funding opportunities
  • Inform public policy on research priorities in allergic diseases and asthma via public engagement and outreach activities.
  • Build an infrastructure that will monitor, analyse and interpret science and research data to identify trends, barriers and opportunities, and strategic imperatives, forecast needs and directions.

The Research & Outreach Committee

    • Mohamed Shamji
    • Ioana Agache
  • Research & Outreach Board Members

    Tomás Chivato, Cezmi A. Akdis,Domingo Barber, Walter Canonica, Stefano del Giacco, Karin Hoffman-Sommergruber, Marek Jutel, Edward Knol, Jürgen Schwarze,Sylwia Smolinska, Stephan Vieths, Liam O’Mahony, Oscar Palomares, Joaquin Sastre, Markus Ollert

  • Research & Outreach Committee Members

    Milena Sokolowska, Matteo Bonini, Helen Brough, Charlotte Mortz, Ludger Klimek, Radoslaw Gawlik, Joana Vitte, Oliver Price, Audrey DunnGalvin, Antonella Cianferoni, Grzegorz Brozek, Katja Bärenfaller, Alexandra Santos, Marina Atanaskovic-Markovic, Montserrat Alvaro, Mohamed Jeebay, Bernardette Eberlein, Anna Sediva, Alessandra Vultaggio, Serge Doan, Liz Angier, Gunter Sturm, Roberto Albertini, Isabella Pali-Schöll

  • Advisory Board

    Harald Renz, Hans-Jürgen Hofmann, Kenji Izuhara, Chrysanthi Skevaki, Paolo Matricardi, Alkis Togias, Kari Nadeau, Isabella Anessi-Maesano, Erika von Mutius, Patrick Holt, Stephen Holgate, Alberto Papi, Helen Reddel, Alvaro Cruz, Param Nair, Knut Brockow, Jean-Christoph Caubet, Sebastian Johnston, Luis Perez de Llano, Jame Gern, Leonard Bacharier, Michael Schatz, Omer Kalayci, Thomas Casale, Peter Barnes, Nicola Hanania, Nikolaos Papadopoulos, Adnan Custovic, Peter Gibson, Marek Kowalski, George du Toit, Omar Usmani, Mariana Castells, Elizabeth Philips, Kian-Fan Chung, Avraham Beigelman, Vibeke Backer, Christer Janson, Ronal van Ree, Clare Lloyd, Hirohisa Saito, Hideaki Morita, Cem Akin, Alberto Mantovani, Victoria del Pozo, Henry McSorley, Gunnar Nielsson, Mario Cazzola, John Holloway, Sevim Bavbek, Dean Naissbitt, Tari Haahtela, Gary Wong, Philippe Eigenmann, Marcus Maurer, Jan Gutermuth, Motohiro Ebisawa, Emma Guttman-Yatsky, Peck Ong, Barbara Ballmer-Weber, Margitta Worm, Thomas Werfel, Montserrat Fernandez Rivas, Sejal Saglani, Paul Turner, Deborah Jarvis, Antonino Romano, Didier Ebo, Hae-Sim Park, Andrea Matucci, Peter Ghazal, Mikaela Odemyr, Breda Flood, Carla Jones, Carina Venter, Isabel Skypala, Sergio Bonini, Ronal Rabin, Vera Mahler, Andreas Bonertz, Karin Sipido, Sirpa Pietikainen, Joao Fonseca, Munir Pirmohamed, Pau Greenberg, Alberto Alvarez-Perea, Florin Dan Popescu, Stephanie Dramburg, Giorgio Colombo, Job van Boven, Ralph Moesges, Derek Chu, Musa Khaitov, Jonathan Corren, Andre Moreira, Otto Spranger, Bruno Giacomo, Holger Schunemann, Ian Adcock, Maria Torres, Bernard Thong, Mona Kidon, Frederic de Blay

  • ROC Groups

    Basic and Clinical Immunology
    Mohamed Shamji, Cezmi Akdis

    Asthma
    Ioana Agache, Matteo Bonini

    Translational
    Marek Jutel, Ioana Agache

    Telemedicine
    Tomas Chivato, Sylwia Smolinska

    Diagnostics
    Domingo Barber, Oscar Palomares

    Methodology
    Giorgio Walter Canonica, Holger Schunemann

    Regulatory
    Stefano Del Giacco, Stefan Vieths

    Environmental
    Joaquin Sastre, Isabella Annesi-Maesano

    Dermatology
    Markus Ollert, Barbara Ballmer-Weber

    ENT
    Ludger Klimek

    Food Allergy
    Alexandra Santos, Isabel Skypala

    Prevention
    Nikolaos Papadopoulos

    Drug Allergy
    Maria Torres

Research Agenda 2022-2023

We propose the following strategic research direction to be prioritised for EAACI funding and support:

1. Environmental science/Planetary Health
2. Real World Evidence. Registries. Health Economics
3. Multidisciplinary approach to patient care from pediatric to adulthood
4. Prevention of allergic diseases and asthma
5. Translational research. Applied clinical research (patient-oriented).
6. Omics. Big data. Artificial Intelligence
7. Vaccinology and immunotherapies
8. Mobile Health. Telemedicine
9. Quality assessment

Publications

Shamji et al. EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network
doi:10.1111/all.14340

Paoletti G, DiBona D, Chu DK, Firinu D, Heffler E, Agache I, Jutel M, Klimek L, Pfaar O, Mösges R, Dunn Galvin A, Genuneit J, Hoffmann HJ, Canonica GW. Allergen Immunotherapy: the growing role of observational and randomised trial “Real-World Evidence”. Allergy. 2021 Feb 14. doi:10.1111/all.14773. Epub ahead of print

Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, Jutel M, Nadeau KC, Palomares O, Rabin RL, Riggioni C, Vieths S, Agache I, Shamji MH. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 Jan 16. doi:10.1111/all.14739. Epub ahead of print

 

EAACI Scientific Network (ESN) Platform

The EAACI Research and Outreach Committee is currently working on the development of an Open Access EAACI Scientific Network (ESN) Platform. The ESN Platform aims to be a facilitator for communication between members and centers providing information on research facilities, capacities, accreditations/certifications/research protocols across EU.

Pan European Health Economics Registry for Allergic Diseases (HEAD)

EAACI, in cooperation with the NAS, is building the first European Registry for the Health Economics of Allergic Diseases. The project is meant to facilitate standardised data collection across different European countries in order to facilitate the in-depth understanding of the burden of allergic diseases and asthma.

Scientific collaborations

BioMed Alliance In vitro Diagnosis Working Group
The EAACI ROC is part of the BioMed Alliance In Vitro Diagnosis Working Group which was established based on decisions in the BioMed Alliance Taskforce on Regulatory Affairs and Medical Devices in 2019. Since a new EU regulation on In Vitro Diagnostics will come into effect in 2022 and will have a major impact on the evaluation and approval process of IVDs, this Working Group has been formed to facilitate member society cooperation on the regulatory aspects of in vitro diagnostics.

BioMed Alliance Academic Clinical Trials Task Force
This task force exists to provide a platform for discussions on academic clinical trials. It facilitates an exchange of best practices and pinpoints the challenges that researchers face in this field. It also aims to better communicate the value of researchers’ work in society and the value of academic clinical trials. It is committed to providing recommendations to reduce inconsistencies in the regulatory framework and advocates for adequate funding.
The EAACI ROC is proudly participating in those activities by being a member of the Task Force.

Moving forward from drug-centered to patient-centered clinical research
https://www.biomedeurope.org/images/eu-policy/Moving_forward_from_drug-centred_to_patient-centred_clinical_research_final.pdf